Company: CSTL
Filing Date: 2025-08-04
Form Type: 10-Q
Source: 0001447362-25-000097
Chunk: 135

Company: CASTLE BIOSCIENCES INC
Filing Date: 2025-08-04
Form: 10-Q
Item: Item 8
Chunk 135
---
 and a report is then delivered to the clinician who ordered the test.

The number of test reports delivered by us are presented in the table below:

Proprietary Dermatologic GEP Tests DecisionDx-MelanomaDecisionDx-SCCDiagnostic GEP offeringDermatologic TotalDecisionDx-UMTissueCypherIDgenetix(1)Grand TotalQ1 20258,621 4,375 926 13,922 470 7,432 2,578 24,402 Q2 20259,981 4,762 1,166 15,909 468 9,170 1,027 26,574 For the six months ended June 30, 202518,602 9,137 2,092 29,831 938 16,602 3,605 50,976 Q1 20248,384 3,577 998 12,959 422 3,429 4,078 20,888 Q2 20249,585 4,277 1,099 14,961 456 4,782 4,903 25,102 For the six months ended June 30, 202417,969 7,854 2,097 27,920 878 8,211 8,981 45,990 Q3 20249,367 4,195 933 14,495 397 6,073 5,045 26,010 Q4 20248,672 4,299 879 13,850 424 6,672 3,125 24,071 For year ended December 31, 202436,008 16,348 3,909 56,265 1,699 20,956 17,151 96,071 

(1)The IDgenetix test was discontinued effective May 2025.

29

For the three and six months ended June 30, 2025, our test report volume increased by 5.9% and 10.8%, respectively, compared to the same period in 2024. Our dermatologic test report volume increased by 6.3% and 6.8% for the three and six months ended June 30, 2025, respectively, compared to the prior period in 2024, largely driven by